Focused On-demand Library for Cleavage and polyadenylation specificity factor subunit 5

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.

The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.

The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.

We utilise our cutting-edge, exclusive workflow to develop focused libraries.

 Fig. 1. The sreening workflow of Receptor.AI

Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.

Our library is unique due to several crucial aspects:

  • Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.
  • By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.
  • The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.
  • Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.







Alternative names:

Cleavage and polyadenylation specificity factor 25 kDa subunit; Cleavage factor Im complex 25 kDa subunit; Nucleoside diphosphate-linked moiety X motif 21; Nudix hydrolase 21; Pre-mRNA cleavage factor Im 68 kDa subunit

Alternative UPACC:

O43809; Q6IB85; Q6NE84


The Cleavage and polyadenylation specificity factor subunit 5, also known as NUDT21, plays a pivotal role in mRNA processing. It is a component of the cleavage factor Im (CFIm) complex, crucial for pre-mRNA 3'-end cleavage and polyadenylation, essential steps in the maturation of pre-mRNA into functional mRNAs. NUDT21 is involved in the recruitment of multiprotein complexes to specific sequences on pre-mRNA, influencing alternative cleavage and polyadenylation (APA) and thereby affecting mRNA 3'-end formation. Its ability to bind to 5'-UGUA-3' elements upstream of polyadenylation signals enhances pre-mRNA 3'-end processing.

Therapeutic significance:

Understanding the role of Cleavage and polyadenylation specificity factor subunit 5 could open doors to potential therapeutic strategies.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.